US EditionPublished • loading... • Updated
Novo Nordisk's weight-loss pill boom faces price war test
Novo says tens of thousands started the Wegovy pill in four months as Lilly’s Foundayo launch draws more than 20,000 users and trails in early demand.
- Tens of thousands of people have started taking Novo Nordisk's Wegovy pill in four months since its launch, forcing investors to rethink the competitive landscape for oral GLP-1s against rival Eli Lilly's Foundayo.
- Novo Nordisk leveraged a three-month head start on Eli Lilly to shape the market narrative, utilizing a $149 monthly entry price and promotional campaigns to combat morning dosing concerns.
- Lilly CEO Dave Ricks reported more than 20,000 people started taking Foundayo in the first few weeks, with 80% of those patients new to GLP-1 drugs, showing strong organic demand.
- Investors will get a fresh look at Wegovy's momentum when Novo Nordisk reports first-quarter results on Wednesday, though BMO Capital Markets analyst Evan David Seigerman notes Lilly still has components to excel.
- Novo Nordisk announced a $500 million manufacturing investment in Ireland to support international demand, as The European Medicines Agency is expected to approve Wegovy later this year.
Insights by Ground AI
4 Articles
4 Articles
Novo Nordisk's weight-loss pill boom faces price war test
Novo Nordisk is seeing brisk early demand for its new weight-loss pill as competition with U.S. rival Eli Lilly intensifies. Investors now want proof that fast-rising prescriptions can offset a bruising price war in obesity drugs.
·United Kingdom
Read Full Article
Novo Nordisk’s head start on GLP-1 pills forces investors to rethink Eli Lilly’s dominance
In this article LLY NVO Follow your favorite stocksCREATE FREE ACCOUNTWegovy semaglutide tablets.Michael Siluk | Universal Images Group | Getty Images When the Wegovy pill launched in January, telehealth provider LifeMD said its business doubled almost overnight. LifeMD went from seeing between 300 and 400 new patients a day to 600 to 1,000 new patients a day, said CEO Justin Schreiber. He knew there would be demand, but that level of interest…
Coverage Details
Total News Sources4
Leaning Left1Leaning Right0Center2Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 33%
C 67%
Factuality
To view factuality data please Upgrade to Premium
